142 related articles for article (PubMed ID: 7908263)
1. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H
Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263
[TBL] [Abstract][Full Text] [Related]
2. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
3. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
[TBL] [Abstract][Full Text] [Related]
4. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
Evans WE; Relling MV
Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
[TBL] [Abstract][Full Text] [Related]
5. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
Dolzan V; Rudolf Z; Breskvar K
Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
[TBL] [Abstract][Full Text] [Related]
6. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC
Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
[TBL] [Abstract][Full Text] [Related]
7. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.
Roots I; Brockmöller J; Drakoulis N; Loddenkemper R
Clin Investig; 1992; 70(3-4):307-19. PubMed ID: 1355678
[TBL] [Abstract][Full Text] [Related]
8. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Broly F; Gaedigk A; Heim M; Eichelbaum M; Morike K; Meyer UA
DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
[TBL] [Abstract][Full Text] [Related]
9. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population.
Hirvonen A; Husgafvel-Pursiainen K; Karjalainen A; Anttila S; Vainio H
Cancer Epidemiol Biomarkers Prev; 1992; 1(6):485-9. PubMed ID: 1284589
[TBL] [Abstract][Full Text] [Related]
10. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
11. CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population.
Sobti RC; Sharma S; Joshi A; Jindal SK; Janmeja A
Biomarkers; 2003; 8(5):415-28. PubMed ID: 14602525
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility.
Xu X; Kelsey KT; Wiencke JK; Wain JC; Christiani DC
Cancer Epidemiol Biomarkers Prev; 1996 Sep; 5(9):687-92. PubMed ID: 8877059
[TBL] [Abstract][Full Text] [Related]
14. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population.
Nakachi K; Imai K; Hayashi S; Kawajiri K
Cancer Res; 1993 Jul; 53(13):2994-9. PubMed ID: 8319207
[TBL] [Abstract][Full Text] [Related]
16. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer.
Kawajiri K; Eguchi H; Nakachi K; Sekiya T; Yamamoto M
Cancer Res; 1996 Jan; 56(1):72-6. PubMed ID: 8548778
[TBL] [Abstract][Full Text] [Related]
17. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
Skoda RC; Gonzalez FJ; Demierre A; Meyer UA
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
[TBL] [Abstract][Full Text] [Related]
18. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer.
Goto I; Yoneda S; Yamamoto M; Kawajiri K
Cancer Res; 1996 Aug; 56(16):3725-30. PubMed ID: 8706015
[TBL] [Abstract][Full Text] [Related]
20. CYP1A1 gene polymorphisms and smoking status as modifier factors for lung cancer risk.
Hussein AG; Pasha HF; El-Shahat HM; Gad DM; Toam MM
Gene; 2014 May; 541(1):26-30. PubMed ID: 24613751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
